NCT04517305View on ClinicalTrials.gov

Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

CompletedOBSERVATIONAL
Enrollment

97

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

May 15, 2021

Study Completion Date

May 15, 2021

Conditions
Breast Cancer
Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04517305 - Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter